IMMUCELL CORP /DE/
ICCCNasdaq
$11.13
↓ -0.0%Jul 17 close · end-of-day
Price
1Y↑ +72.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$100.6M
Enterprise Value
$102.5M
P/E
—
P/S
3.4
P/B
3.5
EV/EBITDA
20.0
PEG
—
FCF Yield
3.4%
Dividend Yield
—
Revenue (TTM)
$29.9M
Net Income (TTM)
-$545,376.00
Free Cash Flow (TTM)
$3.4M
Gross Margin
42.6%
Operating Margin
8.3%
Net Margin
-1.8%
ROE
-1.9%
ROIC
6.4%
Debt / Equity
0.3
Net Cash
-$1.9M
Return 1Y
+68.6%
Company profile
ImmuCell Corporation develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine which quarter of the udder is mastitic.
- CEO
- Michael F. Brigham
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 70
- Headquarters
- Maine
- Website
- immucell.com
Management & directors
- Te Boekhorst Paul Francis OlivierPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
ICCC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$10.4M↑ +28.4%
Diluted EPS$0.21↑ +31.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $15.3M | $19.2M | $18.6M | $17.5M | $26.5M | $27.6M |
| Gross profit | $6.9M | $8.7M | $7.6M | $3.9M | $7.9M | $11.4M |
| Operating income | -$1.4M | $257,385.00 | -$2.3M | -$5.7M | -$1.6M | $1.6M |
| Net income | -$1.0M | -$78,292.00 | -$2.5M | -$5.8M | -$2.2M | -$1.0M |
| Diluted EPS | -$0.14 | -$0.01 | -$0.32 | -$0.75 | -$0.26 | -$0.12 |
| Operating cash flow | $1.3M | $954,170.00 | -$1.5M | -$4.7M | $357,903.00 | $2.5M |
| Free cash flow | -$2.8M | -$1.7M | -$5.5M | -$6.6M | -$107,822.00 | $1.2M |
| Gross margin | 44.7% | 45.0% | 41.2% | 22.1% | 30.0% | 41.4% |
| Operating margin | -9.0% | 1.3% | -12.4% | -32.9% | -6.2% | 6.0% |
| Net margin | -6.7% | -0.4% | -13.4% | -33.1% | -8.1% | -3.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.5M | $6.0M | $7.8M | $8.1M | $6.4M | $5.5M | $7.6M | $10.4M |
| Gross profit | $1.2M | $1.6M | $2.8M | $3.4M | $2.8M | $2.4M | $2.9M | $4.7M |
| Operating income | -$1.4M | -$574,894.00 | $621,394.00 | $1.1M | $569,562.00 | $20,075.00 | -$57,956.00 | $2.0M |
| Net income | -$1.5M | -$701,690.00 | $514,184.00 | $1.4M | $501,880.00 | -$139,748.00 | -$2.8M | $1.9M |
| Diluted EPS | -$0.20 | -$0.09 | $0.09 | $0.16 | $0.06 | -$0.02 | -$0.32 | $0.21 |
| Operating cash flow | $581,780.00 | -$639,331.00 | -$3,051.00 | $1.6M | $1.6M | -$1.2M | $482,541.00 | $3.6M |
| Free cash flow | $471,039.00 | -$727,743.00 | -$199,267.00 | $1.2M | $1.4M | -$1.8M | $310,235.00 | $3.4M |
| Gross margin | 22.5% | 26.3% | 36.5% | 41.6% | 43.7% | 42.9% | 38.2% | 45.0% |
| Operating margin | -25.3% | -9.6% | 8.0% | 13.9% | 8.8% | 0.4% | -0.8% | 19.0% |
| Net margin | -28.0% | -11.7% | 6.6% | 17.9% | 7.8% | -2.5% | -37.4% | 18.7% |
Company news
Jun 26, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-18 | te Boekhorst Paul Francis Olivier· President and CEO | Buy | 8,000 | $9.50 | $75,960.00 | filing |
| 2026-03-20 | BRIGHAM MICHAEL F | Option exercise | 25,000 | $5.84 | $146,000.00 | filing |
| 2026-03-20 | BRIGHAM MICHAEL F | Tax withholding | 24,052 | $6.07 | $145,995.64 | filing |
| 2025-12-04 | te Boekhorst Paul Francis Olivier· President and CEO | Buy | 2,432 | $5.50 | $13,376.49 | filing |
| 2025-12-03 | te Boekhorst Paul Francis Olivier· President and CEO | Buy | 3,598 | $5.05 | $18,151.91 | filing |
| 2025-12-03 | te Boekhorst Paul Francis Olivier· President and CEO | Buy | 3,521 | $5.04 | $17,747.95 | filing |
| 2025-12-03 | te Boekhorst Paul Francis Olivier· President and CEO | Buy | 2,556 | $5.00 | $12,787.67 | filing |
| 2025-12-02 | te Boekhorst Paul Francis Olivier· President and CEO | Buy | 3,708 | $4.87 | $18,052.77 | filing |
| 2025-11-25 | Tomsche David Scott | Buy | 1,633 | $4.77 | $7,781.25 | filing |
| 2025-11-25 | Tomsche David Scott | Buy | 1,633 | $4.76 | $7,773.08 | filing |
Latest 10 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.